market changed now
you know if you follow this
out for now.
their getting out.
Barron's Says VRX Fair Value is $75 A Share-
Article : Valeant Pharmaceuticals: No, It’s Not Worth Breaking Up
By Ben Levisohn
Mizuho’s Irina Koffler contends that Valeant Pharmaceuticals International (VRX) is better off as one company than broken up into its component parts. She explains why:
Ryan Remiorz/Associated Press
Sum of the parts analysis suggests that the business should not be broken up, but rather slowly de-levered and returned to health: We ran a generous sales multiple SOTP analysis to arrive at a $72/share value
Horrible ER And That Included Holiday Sales, Imagine Next Qt No Holidays Sales..
Rotate Out of Apple and Into Facebook
Facebook's incredible mobile growth
Business Insider By Matt Rosoff
6 minutes ago